- Worked in high paced project settings across several industries (healthcare, financial institutions, energy, industrial goods) - Coordinated preparation of program reportings, steering committees and regular operative jour fixes as part of large scale transformations - Reviewed the operating model and energy transition strategy of a German utility - Reviewed the corporate strategy of a pharma company- Worked closely 1:1 with senior stakeholders to support them on their various projects - Prepared detail-oriented C-level presentations, briefings and analysis- Performed various market growth analysis to gain market insights

Humanization of Cas12a2 and assessing it's RNA manipulation capability in mammalian cells.

- Joined a interdisciplinary team in the high paced challenge of SPRIN-D (German Federal Agency of Disruptive Innovation) to research and discuss the use of disruptive new antivirals- Classified the novel CRISPR-Cas system Cas12a2

- Assorted cell toxicity of synthetic vesicles- Co-published a paper on Bottom-up assembly of target-specific cytotoxic synthetic cells

Establishing a new realtime method to analyze synthetic-vesicle immune system interactions for optimizing synthetic drug delivery vessels.

Study of adverse drug effects on development of Alzheimer's using C. elegans as model organism in the lab of Dr. Jan Gruber.